Literature DB >> 1516600

Influence of food on serum ambenonium concentration in patients with myasthenia gravis.

K Ohtsubo1, N Fujii, S Higuchi, T Aoyama, I Goto, T Tatsuhara.   

Abstract

Influence of food on the serum concentration and kinetics ambenonium chloride (AMBC) has been examined in thirteen patients with myasthenia gravis (MG). Mean serum concentrations and Cmax during fasting were higher than those in the non-fasting state. The AUC (0-3 h) was also about four-times larger. The drug effects versus the serum concentration were observed to be anti-clockwise or clockwise. The effective range of the Cmax varied between patients. The unexpected increase in Cmax led to adverse muscarinic actions of AMBC, when the condition was changed from the nonfasting to the fasting state. It is recommended that the dose be changed during non-fasting treatment when adjusting the optimum regimen for patients myasthenia gravis. Patients must be advised to keep to the dosing and dietary schedule in order to avoid unexpected adverse actions to AMBC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516600     DOI: 10.1007/bf00280120

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

2.  Steady state kinetics of pyridostigmine in myasthenia gravis.

Authors:  P S Sørensen; H Flachs; M L Friis; E F Hvidberg; O B Paulson
Journal:  Neurology       Date:  1984-08       Impact factor: 9.910

3.  The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.

Authors:  S C Davison; N M Hyman; A Dehghan; K Chan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

4.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

5.  Factors influencing the intestinal absorption of certain monoquaternary anticholinergic compounds with special reference to benzomethamine [N-diethylaminoethyl-N'-methylbenzilamide methobromide (MC-3199)].

Authors:  R M LEVINE; M R BLAIR; B B CLARK
Journal:  J Pharmacol Exp Ther       Date:  1955-05       Impact factor: 4.030

6.  Plasma concentration of pyridostigmine and effects in myastenia gravis.

Authors:  K Chan; T N Calvey
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

8.  Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.

Authors:  U Breyer-Pfaff; U Maier; A M Brinkmann; F Schumm
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

9.  Transport characteristics of propantheline across rat intestinal brush border membrane.

Authors:  H Saitoh; S Kawai; K Miyazaki; T Arita
Journal:  J Pharm Pharmacol       Date:  1988-03       Impact factor: 3.765

10.  Interaction of tertiary amines and quaternary ammonium compounds with gastrointestinal mucin.

Authors:  H Saitoh; N Hasegawa; S Kawai; K Miyazaki; T Arita
Journal:  J Pharmacobiodyn       Date:  1986-12
View more
  3 in total

1.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

Review 2.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

3.  Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity.

Authors:  Jana Zdarova Karasova; Milos Hroch; Kamil Musilek; Kamil Kuca
Journal:  Neurotox Res       Date:  2015-12-08       Impact factor: 3.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.